DOCSLIB.ORG

ATA/AACE Guidelines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ATA/AACE Guidelines ATA/AACE Guidelines CLINICAL PRACTICE GUIDELINES FOR HYPOTHYROIDISM IN ADULTS: COSPONSORED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND THE AMERICAN THYROID ASSOCIATION Jeffrey R. Garber, MD, FACP, FACE1,2*; Rhoda H. Cobin, MD, FACP, MACE3; Hossein Gharib, MD, MACP, MACE4; James V. Hennessey, MD, FACP2; Irwin Klein, MD, FACP5; Jeffrey I. Mechanick, MD, FACP, FACE, FACN6; Rachel Pessah-Pollack, MD6,7; Peter A. Singer, MD, FACE8; Kenneth A. Woeber, MD, FRCPE9 for the American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice are systematically developed statements to assist health-care professionals in medical decision making for specific clinical conditions. Most of the content herein is based on literature reviews. In areas of uncertainty, professional judgment was applied. These guidelines are a working document that reflects the state of the field at the time of publication. Because rapid changes in this area are expected, periodic revisions are inevitable. We encourage medical professionals to use this information in conjunction with their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances. 988 989 CLINICAL PRACTICE GUIDELINES FOR HYPOTHYROIDISM IN ADULTS: COSPONSORED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND THE AMERICAN THYROID ASSOCIATION Jeffrey R. Garber, MD, FACP, FACE1,2*; Rhoda H. Cobin, MD, FACP, MACE3; Hossein Gharib, MD, MACP, MACE4; James V. Hennessey, MD, FACP2; Irwin Klein, MD, FACP5; Jeffrey I. Mechanick, MD, FACP, FACE, FACN6; Rachel Pessah-Pollack, MD6,7; Peter A. Singer, MD, FACE8; Kenneth A. Woeber, MD, FRCPE9 for the American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults ABSTRACT these recommendations. The strength of the recommen- dations and the quality of evidence supporting each was Objective: Hypothyroidism has multiple etiologies rated according to the approach outlined in the American and manifestations. Appropriate treatment requires an Association of Clinical Endocrinologists Protocol for accurate diagnosis and is influenced by coexisting medical Standardized Production of Clinical Guidelines—2010 conditions. This paper describes evidence-based clinical update. guidelines for the clinical management of hypothyroidism Results: Topics addressed include the etiology, epide- in ambulatory patients. miology, clinical and laboratory evaluation, management, Methods: The development of these guidelines was and consequences of hypothyroidism. Screening, treatment commissioned by the American Association of Clinical of subclinical hypothyroidism, pregnancy, and areas for Endocrinologists (AACE) in association with American future research are also covered. Thyroid Association (ATA). AACE and the ATA assem- Conclusions: Fifty-two evidence-based recommenda- bled a task force of expert clinicians who authored this tions and subrecommendations were developed to aid in article. The authors examined relevant literature and the care of patients with hypothyroidism and to share what took an evidence-based medicine approach that incor- the authors believe is current, rational, and optimal medi- porated their knowledge and experience to develop a cal practice for the diagnosis and care of hypothyroidism. series of specific recommendations and the rationale for A serum thyrotropin is the single best screening test for primary thyroid dysfunction for the vast majority of outpa- tient clinical situations. The standard treatment is replace- ment with L-thyroxine. The decision to treat subclinical hypothyroidism when the serum thyrotropin is less than 10 mIU/L should be tailored to the individual patient. By mutual agreement among the authors and the editors of their respec- INTRODUCTION tive journals, this work is being published jointly in Thyroid and Endocrine Practice. These updated clinical practice guidelines (CPGs) (1–3) *Jeffrey R. Garber, MD, is Chair of the American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on summarize the recommendations of the authors, acting as Hypothyroidism in Adults. All authors after the first author are listed in a joint American Association of Clinical Endocrinologists alphabetical order. (AACE) and American Thyroid Association (ATA) task From the 1Endocrine Division, Harvard Vanguard Medical Associates, Boston, Massachusetts, 2Division of Endocrinology, Beth Israel Deaconess force for the diagnostic evaluation and treatment strategies Medical Center, Boston, Massachusetts, 3New Jersey Endocrine and Diabetes for adults with hypothyroidism, as mandated by the Board Associates, Ridgewood, New Jersey, 4Division of Endocrinology, Mayo of Directors of AACE and the ATA. Clinic, Rochester, Minnesota, 5The Thyroid Unit, North Shore University Hospital, Manhassett, New York, 6Division of Endocrinology, Mount Sinai The ATA develops CPGs to provide guidance and rec- Hospital, New York, New York, 7Division of Endocrinology, ProHealth Care ommendations for particular practice areas concerning thy- Associates, Lake Success, New York, 8Keck School of Medicine, University of roid disease, including thyroid cancer. The guidelines are Southern California, Los Angeles, California, and the 9UCSF Medical Center at Mount Zion, San Francisco, California. not inclusive of all proper approaches or methods, or exclu- Address correspondence to Dr. Jeffrey R. Garber, Endocrinology Division, sive of others. the guidelines do not establish a standard of Harvard Vanguard Medical Associates, 133 Brookline Avenue, Boston MA, care, and specific outcomes are not guaranteed. Treatment 02215. E-mail: [email protected] To purchase reprints of this article, please visit: www.aace.com/reprints. decisions must be made based on the independent judg- Copyright © 2012 AACE. ment of health care providers and each patient’s individual 990 circumstances. A guideline is not intended to take the place was based on specific section titles, thereby avoiding of physician judgment in diagnosing and treatment of par- inclusion of unnecessary detail and exclusion of important ticular patients (for detailed information regarding ATA studies. Compilation of the bibliography was a continual guidelines, see the Supplementary Data, available online at and dynamic process. Once the principal clinical aspects www.liebertpub.com/thy). of hypothyroidism were defined, questions were formu- The AACE Medical Guidelines for Clinical Practice lated with the intent to then develop recommendations that are systematically developed statements to assist health addressed these questions. The grading of recommenda- care professionals in medical decision making for specific tions was based on consensus among the authors. clinical conditions. Most of their content is based on lit- The final document was approved by the American erature reviews. In areas of uncertainty, professional judg- Association of Clinical Endocrinologists (AACE) ment is applied (for detailed information regarding AACE and American Thyroid Association (ATA), and was guidelines, see the Supplementary Data). officially endorsed by the American Association of These guidelines are a document that reflects the cur- Diabetes Educators (AADE), American Academy of rent state of the field and are intended to provide a work- Otolaryngology—Head and Neck Surgery (AAO- ing document for guideline updates since rapid changes in HNS), American College of Endocrinology (ACE), this field are expected in the future. We encourage medi- Italian Association of Clinical Endocrinologists (AME), cal professionals to use this information in conjunction American Society for Metabolic & Bariatric Surgery with their best clinical judgment. The presented recom- (ASMBS), The Endocrine Society of Australia (ESA), mendations may not be appropriate in all situations. Any International Association of Endocrine Surgeons (IAES), decision by practitioners to apply these guidelines must Latin American Thyroid Society (LATS), and Ukranian be made in light of local resources and individual patient Association of Endocrine Surgeons (UAES). circumstances. The guidelines presented here principally address the Objectives management of ambulatory patients with biochemically The purpose of these guidelines is to present an confirmed primary hypothyroidism whose thyroid status updated evidence-based framework for the diagnosis, has been stable for at least several weeks. They do not deal treatment, and follow-up of patients with hypothyroidism. with myxedema coma. The interested reader is directed to the other sources for this information (4). The organization Guidelines for CPGs of the guidelines is presented in Table 1. Current guidelines for CPGs in clinical medicine Serum thyrotropin (TSH) is the single best screening emphasize an evidence-based approach rather than simply test for primary thyroid dysfunction for the vast major- expert opinion (6). Even though a purely evidence-based ity of outpatient clinical situations, but it is not sufficient approach is not applicable to all actual clinical scenarios, for assessing hospitalized patients or when central hypo- we have incorporated this into these CPGs to provide thyroidism is either present or
Load more

Recommended publications
  • Thyroid Hormone Misuse and Abuse
    Endocrine (2019) 66:79–86 https://doi.org/10.1007/s12020-019-02045-1 REVIEW Thyroid hormone misuse and abuse Victor J. Bernet 1,2 Received: 11 June 2019 / Accepted: 2 August 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Thyroid hormone (TH) plays an essential role in human physiology and maintenance of appropriate levels is important for good health. Unfortunately, there are instances in which TH is misused or abused. Such misuse may be intentional such as when individuals take thyroid hormone for unapproved indications like stimulation of weight loss or improved energy. There are instances where healthcare providers prescribe thyroid hormone for controversial or out of date uses and sometimes in supraphysiologic doses. Othertimes, unintentional exposure may occur through supplements or food that unknowingly contain TH. No matter the reason, exposure to exogenous forms of TH places the public at risk for potential adverse side effects. Keywords Thyrotoxicosis ● Thyroid hormone abuse ● Thyroid hormone misuse ● Factitious thyrotoxicosis ● Supplements ● 1234567890();,: 1234567890();,: Analogs Overdose Thyroid hormone misuse and abuse secondary to exogenous TH ingestion that may be unin- tentional or purposeful such as in some cases of Munch- Almost any substance that impacts body physiology and ausen syndrome. Instances of TH misuse can be associated function is at risk for misuse or frank abuse, usually in the with the development of significant side effects. There are misgiven belief that the particular agent whether it be a other instances of chronic, low-grade over treatment with herb, supplement, medication, or hormone has healing TH, which occur for various misreasoning such as weight properties beyond that of which it actually possesses.
    [Show full text]
  • The Subacute Thyroiditis, Since Its First Description by De Quervain (1904), Has Been Reported Under Many Synonyms
    Endocrinol. Japon. 1964, 11 (2), 119～138 STUDIES ON SUBACUTE THYROIDITIS SHOZO SAITO Department of Radiology, School of Medicine, Gunma University, Maebashi The subacute thyroiditis, since its first description by de Quervain (1904), has been reported under many synonyms. Terms given with reference to the histo- logic features of this disease include "pseudotuberculous thyroiditis", "granulo- matous thyroiditis", "gaint-cell thyroiditis", "de Quervain's thyroiditis", "struma granulomatosa" or "struma fibrosa, giant cell variant". The clinical findings have given rise to such names as" acute and subacute nonsuppurative thyroiditis", "acute noninfectious thyroiditis"and"subacute thyroiditis" . In recent writings, the disease is most commonly referred to as subacute thyroiditis. Later, de Quervain and Giordanengo (1936) collected reports of 54 cases of the disease, appearing in the literature since de Quervain's original description, and clearly distinguished it from other forms of thyroiditis. Several years ago, the disease had been considered relatively rare, but with recent advance in endocrinology, more attentions have been drawn by it, and more reports published on it. For the past six years, the author has treated 51 cases of subacute thyroiditis, and obtained findings of interest, which are outlined in this paper. METHODS OF EXAMINATION The disease was confirmed by Silverman's needle biopsy (Crile and Rumsey, 1950; Crile and Hazard, 1951) of the thyroid in 36 of them, and the others were diagnosed by typical clinical symptoms, characteristic results of thyroidal function test and accelerated red cell sedimentation rate and its clinical course. Thyroid function test Basal metabolic rate (BMR) was examined by Knipping's method (normal range•}15%), and serum protein-bound iodine (PBI) by modification of Barker's method (Barker and Humphrey, 1950).
    [Show full text]
  • Hyperthyroidism
    135 Review Article Hyperthyroidism Amanda R. Doubleday, Rebecca S. Sippel Division of Endocrine Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Rebecca S. Sippel, MD. Division of Endocrine Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Clinical Science Center-H4/722, Box 7375, 600 Highland Ave, Madison, WI 53792-3284, USA. Email: [email protected]; Amanda R. Doubleday, DO, MBA. Division of Endocrine Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, K4/739 Clinical Science Center, 600 Highland Ave, Madison, WI 53792-3284, USA. Email: [email protected]. Abstract: Hyperthyroidism is a condition where the thyroid gland produces and secretes inappropriately high amounts of thyroid hormone which can lead to thyrotoxicosis. The prevalence of hyperthyroidism in the United States is approximately 1.2%. There are many different causes of hyperthyroidism, and the most common causes include Graves’ disease (GD), toxic multinodular goiter and toxic adenoma. The diagnosis can be made based on clinical findings and confirmed with biochemical tests and imaging techniques including ultrasound and radioactive iodine uptake scans. This condition impacts many different systems of the body including the integument, musculoskeletal, immune, ophthalmic, reproductive, gastrointestinal and cardiovascular systems. It is important to recognize common cardiovascular manifestations such as hypertension and tachycardia and to treat these patients with beta blockers.
    [Show full text]
  • Disease/Medical Condition
    Disease/Medical Condition HYPOTHYROIDISM Date of Publication: January 27, 2017 (also known as “underactive thyroid disease”; includes congenital hypothyroidism [also known as “neonatal hypothyroidism”] and Hashimoto’s thyroiditis [also known as “autoimmune thyroiditis”]; may manifest as “cretinism” [if onsets during fetal or early life; also known as “congenital myxedema”] or “myxedema” [if onset occurs in older children and adults]) Is the initiation of non-invasive dental hygiene procedures* contra-indicated? No. ◼ Is medical consult advised? – Yes, if previously undiagnosed hypothyroidism or enlarged (or shrunken) thyroid gland is suspected1, in which case the patient/client should see his/her primary care physician. Detection early in childhood can prevent permanent intellectual impairment. – Yes, if previously diagnosed hypothyroidism is suspected to be undermedicated (with manifest signs/symptoms of hypothyroidism) or overmedicated (with manifest signs/symptoms of hyperthyroidism2), in which case the patient/client should see his/her primary care physician or endocrinologist. Major stress or illness sometimes necessitates an increase in prescribed thyroid hormone. Is the initiation of invasive dental hygiene procedures contra-indicated?** Possibly, depending on the certainty of diagnosis and level of control. ◼ Is medical consult advised? – See above. ◼ Is medical clearance required? – Yes, if undiagnosed or severe hypothyroidism is suspected. ◼ Is antibiotic prophylaxis required? – No. ◼ Is postponing treatment advised? – Yes, if undiagnosed hypothyroidism is suspected (necessitating medical assessment/management) or severe hypothyroidism is suspected (necessitating urgent medical assessment/management in order to avoid risk of myxedema coma). In general, the patient/client with mild symptoms of untreated hypothyroidism is not in danger when receiving dental hygiene therapy, and the well managed (euthyroid) patient/client requires no special regard.
    [Show full text]
  • Management of Graves Disease:€€A Review
    Clinical Review & Education Review Management of Graves Disease A Review Henry B. Burch, MD; David S. Cooper, MD Author Audio Interview at IMPORTANCE Graves disease is the most common cause of persistent hyperthyroidism in adults. jama.com Approximately 3% of women and 0.5% of men will develop Graves disease during their lifetime. Supplemental content at jama.com OBSERVATIONS We searched PubMed and the Cochrane database for English-language studies CME Quiz at published from June 2000 through October 5, 2015. Thirteen randomized clinical trials, 5 sys- jamanetworkcme.com and tematic reviews and meta-analyses, and 52 observational studies were included in this review. CME Questions page 2559 Patients with Graves disease may be treated with antithyroid drugs, radioactive iodine (RAI), or surgery (near-total thyroidectomy). The optimal approach depends on patient preference, geog- raphy, and clinical factors. A 12- to 18-month course of antithyroid drugs may lead to a remission in approximately 50% of patients but can cause potentially significant (albeit rare) adverse reac- tions, including agranulocytosis and hepatotoxicity. Adverse reactions typically occur within the first 90 days of therapy. Treating Graves disease with RAI and surgery result in gland destruction or removal, necessitating life-long levothyroxine replacement. Use of RAI has also been associ- ated with the development or worsening of thyroid eye disease in approximately 15% to 20% of patients. Surgery is favored in patients with concomitant suspicious or malignant thyroid nodules, coexisting hyperparathyroidism, and in patients with large goiters or moderate to severe thyroid Author Affiliations: Endocrinology eye disease who cannot be treated using antithyroid drugs.
    [Show full text]
  • Myopathy in Acute Hypothyroidism
    Postgrad Med J: first published as 10.1136/pgmj.63.742.661 on 1 August 1987. Downloaded from Postgraduate Medical Journal (1987) 63, 661-663 Clinical Reports Myopathy in acute hypothyroidism A.W.C. Kung, J.T.C. Ma, Y.L. Yu, C.C.L. Wang, E.K.W. Woo, K.S.L. Lam, C.Y. Huang and R.T.T. Yeung Department ofMedicine, University ofHong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong. Summary: Hypothyroid myopathy has so far been reported in long standing cases ofhypothyroidism. We describe two adult patients with myopathy associated with acute transient hypothyroidism. Both presented with severe muscle aches and cramps, stiffness and spasms. Muscle enzymes were markedly elevated and electromyography in one patient showed myopathic features. Histological changes were absent in muscle biopsy, probably because of the short duration of metabolic disturbance. The myopathy subsided promptly when the hypothyroid state was reversed. Introduction Hypothyroid myopathy has been described in patients however no muscle weakness or symptoms of hypo- with long-standing hypothyroidism.' 3 We report two thyroidism. She had no preceding viral infection. Chinese patients with muscle involvement in acute Examination revealed that the goitre had decreased in copyright. transient hypothyroidism, who improved after rever- size and she was clinically euthyroid. Motor and sal of the hypothyroid state, sensory functions were completely normal. Investigation showed a T4 of 44nmol/l, triiodo- thyronine (T3) 1.2 nmol/I (normal 0.77-2.97 nmol/1), Case reports and TSH 5.1 AIU/ml (normal up to 7). The serum creatine kinase level was 11,940ILmol/min.l (normal Case I 5-165) and the lactic dehydrogenase was 397;Lmol/ min.l (normal 130-275), and glutamic-oxalacetic A 42 year old woman presented at another hospital transaminase was 120limol/min.l (normal 28-32).
    [Show full text]
  • Newborn Screening for Congenital Hypothyroidism: Recommended Guidelines
    American Academy of Pediatrics American Thyroid Association Newborn Screening for Congenital Hypothyroidism: Recommended Guidelines During the past decade newborn screening for of identifying newborns with hyperthyroxinemia congenital hypothyroidism has become an impor- (1:20,000 to 40,000 newborns). tant health activity in most developed countries. On the other hand, this approach will miss in- These screening programs have not only benefited fants who have normal T4 values but elevated TSH patients and their families but also have produced values. Such infants are relatively commonplace in new information about the epidemiology, patho- European programs where initial screening is done physiology, diagnosis, and treatment of thyroid dis- by measurement of TSH. To identify such infants, ease in infancy and childhood. During this period the T4 concentration cutoff (for TSH testing) must of implementation and growth of the screening be increased well into the normal range. programs, a variety of issues and questions arose. Some of these have been resolved, and some have TSH not. The point has now been reached where colla- A majority of European and Japanese programs tion of the combined experiences of the North favor screening by means of primary TSH mea- American programs can address these issues. The surements, supplemented by T4 determinations on reader should understand that what follows reflects those infants with elevated TSH values. With this 0 current opinion and may require changes when the approach, infants with thyroxine-binding globulin results of the next decade of screening are reviewed. deficiency, hypo- or hyperthyroxinemia, or hypo- thalamic-pituitary hypothyroidism will be missed. SCREENING METHOD Until further advances are made in the state of the art of screening, the choice ofthe method should Thyroxine (T4) and Thyroid-Stimulating Hormone be based on the experience of the program, needs (TSH) of the population, and availability of resources.
    [Show full text]
  • Hashimoto Thyroiditis
    Hashimoto thyroiditis Description Hashimoto thyroiditis is a condition that affects the function of the thyroid, which is a butterfly-shaped gland in the lower neck. The thyroid makes hormones that help regulate a wide variety of critical body functions. For example, thyroid hormones influence growth and development, body temperature, heart rate, menstrual cycles, and weight. Hashimoto thyroiditis is a form of chronic inflammation that can damage the thyroid, reducing its ability to produce hormones. One of the first signs of Hashimoto thyroiditis is an enlargement of the thyroid called a goiter. Depending on its size, the enlarged thyroid can cause the neck to look swollen and may interfere with breathing and swallowing. As damage to the thyroid continues, the gland can shrink over a period of years and the goiter may eventually disappear. Other signs and symptoms resulting from an underactive thyroid can include excessive tiredness (fatigue), weight gain or difficulty losing weight, hair that is thin and dry, a slow heart rate, joint or muscle pain, and constipation. People with this condition may also have a pale, puffy face and feel cold even when others around them are warm. Affected women can have heavy or irregular menstrual periods and difficulty conceiving a child ( impaired fertility). Difficulty concentrating and depression can also be signs of a shortage of thyroid hormones. Hashimoto thyroiditis usually appears in mid-adulthood, although it can occur earlier or later in life. Its signs and symptoms tend to develop gradually over months or years. Frequency Hashimoto thyroiditis affects 1 to 2 percent of people in the United States.
    [Show full text]
  • Familial Dysalbuminemic Hyperthyroxinemia: an Underdiagnosed Entity
    Journal of Clinical Medicine Article Familial Dysalbuminemic Hyperthyroxinemia: An Underdiagnosed Entity Xavier Dieu 1,2,* , Nathalie Bouzamondo 1,3, Claire Briet 2,3,4 , Frédéric Illouz 3,4, Valérie Moal 1,3, Florence Boux de Casson 1,3, Natacha Bouhours-Nouet 3,5, Pascal Reynier 1 , Régis Coutant 3,5, Patrice Rodien 2,3,4 and Delphine Mirebeau-Prunier 1,2,3 1 Laboratoire de Biochimie et Biologie Moléculaire, CHU Angers, 4 rue Larrey, CEDEX 9, 49933 Angers, France; [email protected] (N.B.); [email protected] (V.M.); [email protected] (F.B.d.C.); [email protected] (P.R.); [email protected] (D.M.-P.) 2 UMR CNRS 6015-INSERM U1083, 3 rue Roger Amsler, 49100 Angers, France; [email protected] (C.B.); [email protected] (P.R.) 3 Centre de référence des maladies rares de la thyroïde et des récepteurs hormonaux, CHU Angers, 4 rue Larrey, CEDEX 9,49933 Angers, France; [email protected] (F.I.); [email protected] (N.B.-N.); [email protected] (R.C.) 4 Service d’Endocrinologie-Diabétologie-Nutrition, CHU Angers, 4 rue Larrey, CEDEX 9, 49933 Angers, France 5 Service d’Endocrinologie et Diabétologie Pédiatrique, CHU Angers, 4 rue Larrey, CEDEX 9, 49933 Angers, France * Correspondence: [email protected] Received: 5 May 2020; Accepted: 29 June 2020; Published: 3 July 2020 Abstract: Resistance to thyroid hormone (RTH) is a syndrome characterized by impaired sensitivity of tissues to thyroid hormone (TH). The alteration of TH-binding proteins, such as in Familial Dysalbuminemic Hyperthyroxinemia (FDH), can mimic the abnormal serum thyroid tests typical of RTH.
    [Show full text]
  • Screening for Thyroid Dysfunction: U.S. Preventive Services Task Force Recommendation Statement Michael L
    Annals of Internal Medicine CLINICAL GUIDELINE Screening for Thyroid Dysfunction: U.S. Preventive Services Task Force Recommendation Statement Michael L. LeFevre, MD, MSPH, on behalf of the U.S. Preventive Services Task Force* Description: Update of the 2004 U.S. Preventive Services Task Recommendation: The USPSTF concludes that the current ev- Force (USPSTF) recommendation on screening for thyroid idence is insufficient to assess the balance of benefits and harms disease. of screening for thyroid dysfunction in nonpregnant, asymptom- atic adults. (I statement) Methods: The USPSTF reviewed the evidence on the benefits and harms of screening for subclinical and “overt” thyroid dysfunction without clinically obvious symptoms, as well as the Ann Intern Med. 2015;162:641-650. doi:10.7326/M15-0483 www.annals.org effects of treatment on intermediate and final health outcomes. For author affiliation, see end of text. * For a list of USPSTF members, see the Appendix (available at www.annals Population: This recommendation applies to nonpregnant, .org). asymptomatic adults. This article was published online first at www.annals.org on 24 March 2015. he U.S. Preventive Services Task Force (USPSTF) clinicians. Thyroid dysfunction represents a continuum Tmakes recommendations about the effectiveness of from asymptomatic biochemical changes to clinically specific preventive care services for patients without re- symptomatic disease. In rare cases, it can produce life- lated signs or symptoms. threatening complications, such as myxedema coma or It bases its recommendations on the evidence of thyroid storm (1, 2). both the benefits and harms of the service and an as- Subclinical hypothyroidism is defined as an asymp- sessment of the balance.
    [Show full text]
  • Iodine Intake and Prevalence of Thyroid Autoimmunity And
    European Journal of Endocrinology (2012) 167 387–392 ISSN 0804-4643 CLINICAL STUDY Iodine intake and prevalence of thyroid autoimmunity and autoimmune thyroiditis in children and adolescents aged between 1 and 16 years Emilio Garcı´a-Garcı´a, Marı´a A´ ngeles Va´zquez-Lo´pez, Eduardo Garcı´a-Fuentes1, Firma Isabel Rodrı´guez-Sa´nchez2, Francisco Javier Mun˜oz2, Antonio Bonillo-Perales and Federico Soriguer1 Hospital Torreca´rdenas, Unidad de Pediatrı´a, Paraje Torreca´rdenas, s/n, E-04009 Almerı´a, Spain, 1Hospital Carlos Haya, Unidad de Endocrinologı´a y Nutricio´n, Ma´laga, Spain and 2Hospital Torreca´rdenas, Unidad de Biotecnologı´a, Almerı´a, Spain (Correspondence should be addressed to E Garcı´a-Garcı´a; Email: [email protected]) Abstract Objectives: To determine the status of iodine nutrition in children and adolescents in Almerı´a, Spain. To calculate prevalence of thyroid autoimmunity (TA) and autoimmune thyroiditis (AT) in pediatric ages and to research into associated factors. Methods: Cross-sectional epidemiological study. By a multistage probability sampling 1387 children and adolescents aged between 1 and 16 were selected. Physical examination was carried out including neck palpation. Parents were asked about eating habits as well as about social and demographic aspects. Urinary iodine, free thyroxine, TSH, antiperoxidase and antithyroglobulin antibodies were measured. TA was diagnosed when any antibody was positive and AT when autoimmunity was associated with impaired thyroid function or goitre. Results are shown using percentages (and its 95% confidence interval). To study associated factors we used multiple logistic regression, quantifying the relation with odds ratio (OR), and multiple lineal regression.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]